Related Experiment Video
Updated: Mar 7, 2026
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
High-density Lipoprotein and Low-density Lipoprotein Therapeutic Approaches in Acute Coronary Syndromes
Emmanuel Androulakis1, Effimia Zacharia2, Nikolaos Papageorgiou3
1St George's University Hospital, London, United Kingdom.
Insights
New therapies targeting low-density lipoprotein cholesterol (LDL) and high-density lipoprotein (HDL) show promise for acute coronary syndromes (ACS). Further research is needed to confirm benefits for ACS patients with LDL- or HDL-targeted treatments.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Background:
- Oxidized low-density lipoprotein cholesterol (LDL) destabilizes atherosclerotic plaques, increasing acute coronary syndromes (ACS) risk.
- High-density lipoprotein (HDL) is recognized for its anti-atherogenic properties.
- While novel HDL-targeted therapies and apoA-I upregulation show potential, past HDL treatments have not significantly improved ACS outcomes.
Purpose of the Study:
- To review the current landscape of LDL- and HDL-targeted therapies for managing atherosclerotic plaque vulnerability in ACS.
- To evaluate the efficacy and safety of emerging pharmacological interventions for hyperlipidemia in the context of ACS.
Main Methods:
- Review of recent clinical studies and pharmacological advancements in lipid-lowering therapies.
- Analysis of data on novel drugs including PCSK9 inhibitors, apolipoprotein B inhibitors, and HDL-modulating agents.
Main Results:
- Emerging LDL-targeted therapies (PCSK9 inhibitors, apolipoprotein B inhibitors) demonstrate effectiveness and safety in hyperlipidemia.
- Novel HDL-targeted drugs and HDL mimetics increase HDL levels, with some showing benefits beyond HDL-related effects.
- Despite advancements, definitive clinical benefits of HDL-targeted therapies in ACS patients remain to be confirmed.
Conclusions:
- Current data suggest potential cardiovascular benefits from novel LDL- and HDL-targeted therapies in ACS patients.
- Further research is essential to ascertain whether ACS patients would benefit most from LDL-targeted, HDL-targeted, or combination therapies.
Background:
Low-density lipoprotein cholesterol (LDL), and especially its oxidized form, renders the atherosclerotic plaque vulnerable to rupture in acute coronary syndromes (ACS). On the other hand, high-density lipoprotein (HDL) is considered an anti-atherogenic molecule. The more recent HDL-targeted drugs may prove to be superior to those used before. Indeed, delipidated HDL and HDL mimetics are efficient in increasing HDL levels, while the apoA-I upregulation with RVX-208 appears to offer a clinical benefit which is beyond the HDL related effects. HDL treatment however has not shown a significant improvement in the outcomes of patients with ACS so far, studies have therefore focused again on LDL. In addition to statins and ezetimibe, novel drugs such as PSCK9 inhibitors and apolipoprotein B inhibitors appear to be both effective and safe for patients with hyperlipidemia.
Conclusion:
Data suggest these could potentially improve the cardiovascular outcomes of patient with ACS. Yet, there is still research to be done, in order to confirm whether ACS patients would benefit from LDL- or HDL-targeted therapies or a combination of both.
Related Concept Videos
01:27Coronary Artery Disease V: Interprofessional Care
01:26Atherosclerosis III: Management
01:26Coronary Artery Disease IV: Preventive Measures
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:26Angina IV: Management